Hep Magazine

Hep is a highly regarded print and online resource dedicated to individuals affected by viral hepatitis. Since its inception in 2010, Hep and its website, HepMag.com, have provided top-quality editorial content, making them a trusted source for education and support for those living with hepatitis. At Smart + Strong, Hep's parent organization, we believe that having access to reliable health information, feeling empowered to advocate for your own needs, and connecting with others facing similar health challenges can significantly improve your chances of thriving. Smart + Strong produces health-oriented magazines and websites that unite a wide range of individuals to disseminate crucial information. These platforms allow you to share your experiences with healthcare providers, insurance companies, the media, government entities, and each other, highlighting what it means to live with and overcome various health issues.

Consumer

English

Magazine, Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#3320592

United States

#1037893

Health/Health Conditions and Concerns

#2994

Traffic sources

Monthly visitors

Articles

FDA Approves Mavyret for Acute Hepatitis C

2 weeks ago | hepmag.com | Liz Highleyman

On June 11, the Food and Drug Administration (FDA) expanded the approval of Mavyret (glecaprevir/pibrentasvir), from AbbVie, to include treatment of acute hepatitis C, meaning infection within the previous six months. This enables providers to start treatment immediately at the time of diagnosis. Over years or decades, chronic hepatitis C virus (HCV) infection can lead to serious liver complications, including fibrosis, cirrhosis and liver cancer.
Senators Introduce Cure Hepatitis C Act to Increase Access to Treatment

3 weeks ago | hepmag.com | Liz Highleyman

Sen. Bill Cassidy, MD (R-LA)—one of the four medical doctors serving in the Senate—and Sen. Chris Van Hollen (D-MD) yesterday introduced bipartisan legislation that aims to help more Americans access lifesaving treatment for hepatitis C. “We can virtually eliminate hepatitis C in a fiscally responsible way,” Cassidy said in a news release. “Curing hepatitis C makes Americans healthy again while also saving the federal government billions by eliminating the need for chronic care.
Pregnant Women With MASLD Have Triple Preterm Birth Risk

3 weeks ago | hepmag.com | Sukanya Charuchandra

Expectant mothers with metabolic dysfunction-associated fatty liver disease (MASLD) face a more than threefold higher risk of delivering prematurely, even after accounting for obesity, family health history and liver disease severity, according to study findings were published in EClinicalMedicine.
Weight-Loss Meds Reduce Risk of Obesity-Related Cancers

3 weeks ago | hepmag.com | Liz Highleyman

Use of popular weight-loss medications, such as semaglutide and tirzepatide, was associated with a moderately lower risk for obesity-related cancers, especially colon and rectal cancer, and reduced overall mortality compared with another widely used class of diabetes drugs, according to a study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago.
Study Backs Early Hepatitis B Treatment-Even Without Liver Damage

1 month ago | hepmag.com | Sukanya Charuchandra

In a major clinical trial across South Korea and Taiwan, researchers found that starting antiviral therapy for hepatitis B early—before signs of liver damage appear—significantly reduced the risk for liver cancer and other severe complications. These findings, published in The Lancet Gastroenterology & Hepatology, support updated treatment guidelines that primarily focus on viral load, not liver enzyme levels.
Microbiota Transplant Cuts Hepatic Encephalopathy in People With Cirrhosis

1 month ago | hepmag.com | Sukanya Charuchandra

For people with liver cirrhosis and recurrent hepatic encephalopathy, fecal microbiota transplantation (FMT) may offer a new line of defense. Researchers found that FMT—delivered by capsule or enema and from either vegan or omnivorous donors—was safe and associated with significantly lower rates of encephalopathy recurrence, according to research published in the Journal of Hepatology. Notably, the benefits were associated with changes in gut bacteria types.
Are Weight-Loss Drugs the Answer for Fatty Liver Disease?

1 month ago | hepmag.com | Liz Highleyman

Treatment of metabolic dysfunction-associated steatohepatitis (MASH) may soon be added to the growing list of indications for GLP-1 agonists such as semaglutide (sold as Ozempic and Wegovy). Some experts, however, stress that liver-directed medications are still needed for people with fibrosis or cirrhosis.
Fatty Liver Disease Is Expected to Skyrocket By 20250

Mar 24, 2025 | hepmag.com | Sukanya Charuchandra

Without better detection and effective treatment, the clinical burden of metabolic dysfunction-associated fatty liver disease (MASLD) is expected to rise dramatically over the next 30 years, with cases of decompensated cirrhosis more than tripling, liver cancer nearly doubling and liver transplants increasing almost fourfold. Researchers generated these projections, which were published in JAMA Network Open, using a simulation model.
HIV/HBV/HDV Triple Infection Linked to Liver-Related Death

Feb 24, 2025 | hepmag.com | Sukanya Charuchandra

Among people with HIV and hepatitis B virus (HBV) coinfection, “superinfection” with hepatitis D virus (HDV) is a serious risk factor for liver-related death despite antiviral treatment, according to study findings published in Clinical Infectious Diseases. HIV and hepatitis B have overlapping transmission routes, and around 10% of people living with HIV worldwide also have HBV.
Efruxifermin Improves Liver Cirrhosis in People With MASH

Jan 29, 2025 | hepmag.com | Liz Highleyman

Efruxifermin, a fibroblast growth factor analog, led to regression of liver fibrosis in people with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis, Akero Therapeutics announced this week. If approved, it could become the first medication for people with the most advanced stage of fibrosis due to fatty liver disease.